medigraphic.com
ISSN 0035-0052 (Print)

2026, Number 1

<< Back Next >>

Rev Mex Pediatr 2026; 93 (1)

Stevens-Johnson syndrome induced by trimethoprim-sulfamethoxazole

Pachicano-Leal JLT, Liñán-Vázquez A

Language: Spanish
References: 19
Page: 32-35
PDF size: 1365.29 Kb.


ABSTRACT

Introduction: the spectrum of Stevens-Johnson syndrome (SJS) - toxic epidermal necrolysis - constitutes a serious allergic dermatological condition, frequently associated with commonly prescribed medications. Its timely recognition and treatment are essential to improve prognosis. Objective: to describe the management and evolution of a pediatric patient with SJS. Case description: a 2-year-10-month-old female patient was admitted to the emergency department after ingesting trimethoprim/sulfamethoxazole (TMP/SMZ) with fever, necrotic-hemorrhagic ulcers on her lips, and skin involvement of her extremities. She received supportive treatment and showed favorable clinical evolution in less than a week. Conclusion: TMP/SMZ can be associated with severe drug eruptions; in the presence of a prodromal condition with mucocutaneous involvement, SJS should be suspected.


REFERENCES

  1. Thomas BA. The so-called Stevens-Johnson syndrome. Br MedJ. 1950; 1(4667): 1393-1397. doi: 10.1136/bmj.1.4667.1393.

  2. Rodríguez B, Trejo N, Alfaro A, Rodríguez R, González D.Síndrome de Stevens-Johnson inducido por paracetamol en unpaciente pediátrico. Dermatol Rev Mex. 2021; 65(6): 991-998. doi:10.24245/dermatolrevmex.v65i6.7174

  3. Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Volume1. Mosby; 2018.

  4. Arenas R. Atlas de dermatología: diagnóstico y tratamiento. 7aed. McGraw-Hill Interamericana; 2019.

  5. Tabet A, Al-Nasseri A, Hall C, He C, Abernathy J. Stevens-Johnsonsyndrome in a patient on concomitant treatment with levetiracetamand trimethoprim/sulfamethoxazole. Am J Case Rep. 2024; 22(25):e942982. doi: 10.12659/AJCR.942982.

  6. Urias-López L. Síndrome Stevens Jonhson: reporte de casoclínico. Rev Sanid Milit. 2023; 77(3): 1-9.

  7. Guía de Práctica Clínica Diagnóstico y Tratamiento del Síndromede Stevens Johnson/necrólisis epidérmica tóxica, México: InstitutoMexicano del Seguro Social; 2011. Disponible en: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/398GER.pdf

  8. Alerhand S, Cassella C, Koyfman A. Stevens-Johnson syndromeand toxic epidermal necrolysis in the pediatric population: areview. Pediatric Emerg Care. 2016; 32(7): 472-476. doi: 10.1097/PEC.0000000000000840.

  9. Antoon J, Goldman J, Lee B, Schwartz A. Incidence, outcomes,and resource use in children with Stevens-Johnson syndrome andtoxic epidermal necrolysis. Pediatr Dermatol. 2018; 35(2): 182-187.doi: 10.1111/pde.13383.

  10. Lee E, Knox C, Phillips E. Worldwide prevalence of antibioticassociatedStevens-Johnson syndrome and toxic epidermalnecrolysis: a systematic review and meta-analysis. JAMA Dermatol.2023; 159(4): 384-392. doi: 10.1001/jamadermatol.2022.6378.

  11. Sibbald C, Putterman E, Micheletti R, Treat J, Castelo-Soccio L.Retrospective review of drug-induced Stevens-Johnson syndromeand toxic epidermal necrolysis cases at a pediatric tertiary careinstitution. Pediatric Dermatol. 2020; 37(3): 461-466. https://doi.org/10.1111/pde.14118

  12. Wanat K, Milan J, Klekotka P. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated withtrimethoprim-sulfamethoxazole. J Am Acad Dermatol. 2009; 60(4):589-594. Available in: https://doi.org/10.1016/j.jaad.2008.11.884

  13. Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnsonsyndrome and toxic epidermal necrolysis: a review of diagnosisand management. Medicina (Kaunas). 2021; 57(9): 895. https://doi.org/10.3390/medicina57090895

  14. Chi MH, Chung WH, Hui RC, Chen CB, Lu CW, Chiu TM et al.Clinical features and outcomes in children with Stevens-Johnsonsyndrome and toxic epidermal necrolysis. J Dermatol. 2022; 49(9):895-902. https://doi.org/10.1111/1346-8138.16476

  15. Martínez-Cabriales SA, Gómez-Flores M, Ocampo-Candiani J.Actualidades en farmacodermias severas: síndrome de Stevens-Johnson (SSJ) y necrólisis epidérmica tóxica (NET) [News insevere clinical adverse drug reactions: Stevens-Johnson syndrome(SJS) and toxic epidermal necrolysis (TEN)]. Gac Med Mex. 2015;151(6): 777-787.

  16. Vanfleteren I, Van Gysel D, De Brandt C. Stevens-Johnsonsyndrome: a diagnostic challenge in the absence of skin lesions.Pediatr Dermatol. 2003; 20(1): 52-56. https://doi.org/10.1046/j.1525-1470.2003.03012.x

  17. Sorrell J, Anthony L, Rademaker A, Belknap S, Callahan S, WestD et al. Score of toxic epidermal necrosis predicts the outcomesof pediatric epidermal necrolysis. Pediatr Dermatol. 2017; 34(4):433-437. doi: 10.1111/pde.13172.

  18. Wasuwanich P, So J, Chakrala T, Chen J, Motaparthi, K.Epidemiology of Stevens-Johnson syndrome and toxic epidermalnecrolysis in the United States and factors predictive ofoutcome. JAAD Int. 2023; 13: 17-25. https://doi.org/10.1016/j.jdin.2023.06.014

  19. Bonilla-Rojas J, Hernández-Cabezza A, Villasís-KeeverMÁ, Serret-Montoya J, Cárdenas-Navarrete R. Síndrome deStevens-Johnson en pediatría, reporte de un caso por el uso deantiepilépticos. Rev Mex Pediatr. 2018; 85(6): 226-229.




2020     |     www.medigraphic.com